C5 inhibitors can defend against biological attacks and control diseases caused by immune responses.

Bruton's Tyrosine Kinase (BTK) inhibitors present a promising treatment for B-cell malignancies. Over the past decade, numerous clinical trials involving BTK inhibitors with anticancer potential have commenced, signaling a bright future for BTK inhibitors.

BRD4 inhibitors, developed using computer-assisted drug design, are viewed as potential therapies for various diseases due to BRD4's involvement in gene expression, chromatin remodeling, cell cycle, and cancer.

BRAF mutation is one of the significant therapeutic targets for various solid tumors, with BRAF inhibitors representing a major form of targeted combination therapy for BRAF mutation-positive solid tumors.

β-Inhibitors can inhibit the activity of β-lactamase inhibitors produced by drug-resistant bacteria. They are typically used in combination with β-lactam antibiotics to protect the β-lactam antibiotics from hydrolysis, thereby inhibiting enzyme-resistant bacteria.

The overexpression of BCL-2 protein allows tumor cells to evade apoptosis and to become resistant to a variety of anti-tumor drugs. Bcl-2 inhibitors are a new type of anti-cancer drug developed to target the mechanism of apoptosis, promoting cell death.

ATR, a core DDR kinase, senses replication stress and signals S and G2/M checkpoints to initiate DNA repair. It's a hot target in anti-cancer drug development, with some ATR inhibitors already in clinical trials.

Aromatase converts androstenedione to estrogens. In postmenopausal women, it mainly comes from adrenal glands. Aromatase inhibitors target high-risk groups, combined with OFS for endocrine therapy.

The Androgen Receptor (AR) regulates prostate homeostasis and cancer cell survival. AR-targeted therapy boosts survival rates in advanced prostate cancer patients ineffectively cured by surgery or radiation.

AMPK is a critical metabolic regulator, responsible for maintaining and restoring energy balance at the cellular and physiological levels. Studying AMPK targets and their microenvironment helps clarify how AMPK restores energy homeostasis.

AKT (Protein Kinase B), a pivotal player in PI3K/AKT/m-TOR signaling pathway, is a prospective drug target clinically. Its activation is crucial for cell survival and growth, implicating in tumorigenesis and metastasis. Research indicates AKT over-activation in over 50% of tumors.

Acetylcholinesterase (AChE), the primary cholinesterase in the body, is an enzyme catalyzing the breakdown of acetylcholine and of some other choline esters that function as neurotransmitters.